Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
Top tips: type 2 diabetes
Dr Kevin Fernando provides top tips on diagnosing and managing type 2 diabetes and identifying people at high risk
An innovative diabetes service redesign in Wakefield
Dr Dinesh Nagi provides insight into an integrated model of care provided by primary care and specialist diabetes teams
Structured education for people with diabetes can improve quality of life
Dr Kevin Fernando discusses the updated NICE quality standard on diabetes in adults: education about diabetes can motivate patients and enable self-management
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
Educational resources
Formulary decision guide: Ozempic®▼ (semaglutide)
Information intended for healthcare professionals only. This formulary decision guide was developed from content supplied by Novo Nordisk in a format developed by Guidelines in Practice. It has been reviewed by Novo Nordisk, who commissioned the development of the formulary decision guide.
Formulary decision guide: Jardiance®▼ (empagliflozin) film-coated tablets
Information intended for healthcare professionals only. This formulary decision guide was initiated, funded, and reviewed by Boehringer Ingelheim Limited and Lilly Diabetes Alliance. The format was developed by Guidelines in Practice. Prescribing information can be found on page 2 of the formulary decision guide.
Formulary decision guide: Trajenta® (linagliptin) 5 mg film-coated tablets
Promotional material from Boehringer Ingelheim Limited and Lilly Diabetes Alliance
Video: SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes
The development of this Guidelines video has been supported by an educational grant from Napp Pharmaceuticals Limited. Napp Pharmaceuticals Limited had no influence over the selection of the speaker or the content of the video, and checked the final files for technical accuracy only.
Related Guidelines summaries
-
Pancreatic exocrine insufficiency guideline
What are the signs of pancreatic exocrine insufficiency in diabetes? This concise management algorithm covers symptoms, investigations, and referral.
-
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
-
WEDS diabetes screening guideline
Find out in this summary when HbA1c should not be used as a sole test to diagnose diabetes. Includes an algorithm for diagnosis and treatment.